Treating heart failure with cardiac contractility modulation electrical signals

Area of Science:

• Cardiology
• Biomedical Engineering

Background:

• Significant advances in pharmacologic treatment for chronic heart failure (HF) have been achieved over the last two decades.
• While effective, current medications like ACE inhibitors, beta-blockers, and aldosterone antagonists delay but do not halt the progression of advanced HF.

Purpose of the Study:

• To review the progress in the development and implementation of cardiac contractility modulation (CCM) as a device-based therapy.
• To highlight CCM as a potential treatment for patients with advanced heart failure.

Main Methods:

• Review of existing literature on pharmacologic and device-based therapies for HF.
• Focus on the development and clinical implementation of CCM devices.

Main Results:

• Pharmacologic therapies have reduced mortality and morbidity in HF patients with reduced ejection fraction.
• Despite optimal medical therapy, many patients with advanced HF continue to deteriorate, necessitating further interventions.
• Device therapies, including CCM, are emerging to address the unmet needs in advanced HF management.

Conclusions:

• Cardiac contractility modulation (CCM) is an investigational device-based therapy utilizing electrical signals for advanced HF treatment.
• CCM represents a promising area of development for managing patients with intractable heart failure.